QNCX Quince Therapeutics, Inc.
Quince Therapeutics, Inc. (QNCX) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $1.44 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +7.1% since its last earnings release on August 14, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Quince Therapeutics, Inc.
Quince Therapeutics Inc. is a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases. The company's product pipeline includes NOV004. Quince Therapeutics Inc., formerly known as Cortexyme Inc., is based in Calif.
Sector
Healthcare
Industry
Biotechnology